Finn Eggert Sørensen
Keine laufenden Positionen mehr
Profil
Finn Eggert Sørensen served as Chairman at Bok Holding A and Director at Neurokey A.
He was also the Chief Business Officer & Executive Vice President at NTG Nordic Transport Group A from 2009 to 2013.
Prior to that, he held Principal positions at Takeda A, Nordisk Gentofte A, Benzon Pharma A, Proteo Target ApS, Serendex Pharmaceuticals A, and Contera Pharma ApS.
Mr. Sørensen received his undergraduate and graduate degrees from Danmarks Farmaceutiske Universitet.
Ehemalige bekannte Positionen von Finn Eggert Sørensen
Unternehmen | Position | Ende |
---|---|---|
Neurokey A/S
Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | Direktor/Vorstandsmitglied | 30.07.2010 |
Takeda A/S
Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Präsident | - |
SERENDEX PHARMACEUTICALS A/S | Corporate Officer/Principal | - |
Contera Pharma ApS
Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Corporate Officer/Principal | - |
Proteo Target ApS | Corporate Officer/Principal | - |
Ausbildung von Finn Eggert Sørensen
Danmarks Farmaceutiske Universitet | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
NTG NORDIC TRANSPORT GROUP A/S | Transportation |
Private Unternehmen | 8 |
---|---|
Bok Holding A/S
Bok Holding A/S BiotechnologyHealth Technology Bok Holding A/S is a holding company that operates as a biotechnology company that researches and develops cancer treatment solutions. It develops the ZAS platform technology which efficiently enhances the effect of current anti-cancer drugs and reduces toxicity. The firm employs molecular techniques commonly known as molecular breeding or directed enzyme evolution which can activate anti-cancer drugs. The company was founded by Zoran Gojkovic on November 22, 2001 and is headquartered in Gentofte, Denmark. | Health Technology |
Neurokey A/S
Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | Health Technology |
Nordisk Gentofte A/S | |
Benzon Pharma A/S | |
Proteo Target ApS | |
Contera Pharma ApS
Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |
Serendex Pharmaceuticals A/S
Serendex Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Serendex Pharmaceuticals A/S engages in the research and development of pharmaceuticals for respiratory conditions. It develops drugs to treat respiratory conditions such as Pulmonary Alveolar Proteinosis, Bronchiectasis, Cystic Fibrosis related lung infections and Diffuse Alveolar Hemorrhage. The company was founded by Lars Heslet on October 31, 2008 and is headquartered in Horsholm, Denmark. | Health Technology |
Takeda A/S
Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Finance |